AGM Information • Jun 2, 2021
AGM Information
Open in ViewerOpens in native device viewer
PRESS RELEASE
Chassieu, 02 june 2021
The General Meeting of Amoéba shareholders, convened on May 27, 2021 at 9 a.m. at the Company's registered office, did not reach the quorum required to vote on the ordinary and extraordinary resolutions.
Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be held on second call on:
for the purpose of ruling on the same agenda as the first convocation notice, published in the Bulletin des Annonces Légales Obligatoires (BALO) of 10 may 2021.
The notice of the second convocation including the agenda was published in the Bulletin des Annonces légales Obligatoires (BALO) of June 2, 2021. The terms and conditions of participation and voting at the Meeting are set out in this notice.
The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:
As of today, Wednesday, June 2, log on to the website of your financial intermediary dedicated to the management of your AMOEBA shares, with your usual access codes and vote online if you hold your shares in one of the following banks (list of banks offering access to the VOTACESS platform): Banque Populaire, Banque Postale, BNP Paribas, Bourse Direct, Boursorama, Caisse d'Epargne, Crédit Agricole, Crédit Mutuel, CIC, HSBC, Milleis, Natixis, Société Générale.
Find all the information you need to vote by post or give proxy to the Chairman on our dedicated page: https://amoeba-nature.com/en/investor/general-assembly/
We are at your disposal to provide you with any additional information on voting procedures by calling+ 33 (0)1 53 65 68 68 or by email at [email protected]
In the context of the coronavirus epidemic (COVID-19), the procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website (http://www.amoeba-nature.com/Investors/General-assembly).
Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK
Amoéba Valérie FILIATRE Directeur Général Adjoint +33 4 26 69 16 00 [email protected]
Relations investisseurs & Presse Grégory BOSSON / Mathieu CALLEUX +33 1 53 65 37 90 /91 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.